Close
Nordic 9Nordic 9

Omega Funds (investor - Private Equity)

United States omegafunds.net
See something wrong or missing? Let us know
Offices:Boston

Omega Funds is an American investment firm that creates and invests in life sciences companies that target the world’s most urgent medical needs.

Average round investment:61.3M USD
Average number per year:2.0
Distribution: 2025 (3)2024 (1)2023 (3)2022 (3)2021 (1) See the entire list
Portfolio companies: United Kingdom NRG TherapeuticsNorway ArtbioDenmark Ousia Pharma See the entire list
Mostly invests in: United Kingdom United Kingdom (3) Health services (14)
See the entire list

Showing 3 of 14 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Omega Funds mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Omega Funds

Name Criteria
Switzerland HBM Healthcare Investments
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland, Denmark, Germany
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Prime Movers Labs
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland, United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States HOF Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Germany
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Lightstone Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing, Hardware
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Elevage Medical Technologies
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Hardware
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Canada Sixty Degree Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland, Germany
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Honeywell Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Pharma, Manufacturing, Hardware
  • Similar business models: B2B
  • Common investees countries: Switzerland, United Kingdom, Germany, Spain
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
United States Longitude Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Hardware
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Denmark Maj Invest
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Norway, Denmark
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
United States Samsara BioCapital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland, United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Top